2022
Interim Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes
Strober B, Bukhalo M, Armstrong A, Pariser D, Kircik L, Parhami S, Montgomery P, Dickerson T. Interim Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes. SKIN The Journal Of Cutaneous Medicine 2022, 6: 458-462. DOI: 10.25251/skin.6.6.2.Peer-Reviewed Original ResearchPhysician prescribing behaviorPatient outcomesPsoriasis patientsPrescribing behaviorClinical utilityExact testMatch StudyChoice of biologicsFisher's exact testPhysician decision makingBiologic selectionBiologic-naïveClinical outcomesLesional skinPsoriasis treatmentDrug classesPatient responsePatient managementWeek 4PatientsPhysician behaviorPhysiciansHealthcare systemBaselineInterim measurements
2021
A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment Paradigm
Strober B, Pariser D, Deren-Lewis A, Dickerson T, Lebwohl M, Menter A. A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment Paradigm. Dermatology And Therapy 2021, 11: 1851-1860. PMID: 34275121, PMCID: PMC8484423, DOI: 10.1007/s13555-021-00573-1.Peer-Reviewed Original ResearchPatient outcomesCommunity dermatologistsPsoriasis treatment responseNon-responding patientsFirst-line therapySuboptimal patient outcomesBiologic switchingBiologic agentsPsoriasis managementTherapy utilizationBiologic classesTherapeutic responseTreatment paradigmTreatment responseClinical utilityBiologic drugsPatientsDrug selectionMethodsA surveyPrior authorizationDermatologistsFirst choiceTrialsBiologic responsePrecision medicine